TROP2 has been confirmed to be highly expressed in various malignant tumors, such as ovarian carcinoma, cervical cancer 6-10, lung cancer 11,12, pancreatic cancer 13 and prostate cancer 14. Here, TACSTD2 is linked to lung cancer.